Filing Analysis
USANA Health Sciences, Inc. has entered into a definitive agreement to acquire a controlling interest (78.85%) in Hiya Health Products, LLC, a direct-to-consumer online retail business specializing in children's vitamins and supplements.
🚩 Red Flags
- Significant use of debt: The $205 million acquisition relies heavily on existing credit facilities and cash reserves.
- Contingent liabilities: The 'Put Right' starting in 2028 creates a potential future cash outflow obligation based on EBITDA multiples.
📋 Key Facts
- Acquisition of 78.85% membership interest in Hiya Health Products, LLC via a merger with Karate Merger Sub, LLC.
- Total consideration for the 78.85% stake is $205 million.
- Funding sources: $200 million from cash on hand and the balance from borrowings under existing credit facility.
- The remaining 21.15% interest (Class B Units) will be held by Qualified Holders in exchange for cash consideration.
- The transaction includes 'Put Rights' allowing Class B holders to force the company to purchase units starting April 30, 2028.
- Purchase price for remaining units is based on a multiple of Hiya's Adjusted EBITDA.
USANA Health Sciences, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 28, 2024. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Company announced Q3 2024 financial results on October 22, 2024.
- The reporting period ended September 28, 2024.
- Management held/is holding a conference call to discuss results and provide commentary.
- Exhibits include a press release (99.1) and Management Commentary (99.2).
USANA Health Sciences, Inc. filed an 8-K to announce the release of its second quarter 2024 financial results and management commentary. The filing serves as a formal notification that earnings data is being made public via press release and an investor conference call.
📋 Key Facts
- Company announced Q2 2024 financial results on July 23, 2024.
- The reporting period ended June 29, 2024.
- Management will host a conference call to discuss results and provide a 'Management Commentary'.
- Financial information was furnished rather than filed under Section 18 of the Exchange Act.
USANA Health Sciences reported the results of its Annual Meeting of Shareholders held on May 6, 2024. The meeting included the election of eight directors and advisory votes on auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting of Shareholders held on May 6, 2024.
- Quorum reached with 17,520,055 shares (approx. 91%) represented by proxy or in person.
- Eight individuals were elected to the Board of Directors, including Kevin G. Guest and Xia Ding.
- Shareholders ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2024 with 17,458,617 votes in favor.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay) with 16,559,671 votes in favor.
USANA Health Sciences, Inc. filed an 8-K to announce its financial results for the first quarter ended March 30, 2024. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Report date: April 30, 2024
- Reporting period: First Quarter ended March 30, 2024
- The filing includes a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2)
- Management held/is holding a conference call to discuss results with investors
USANA Health Sciences, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 30, 2023. The filing includes a press release and management commentary regarding the company's recent operations.
📋 Key Facts
- Reported date of event: February 6, 2024.
- Financial results cover the fourth quarter and fiscal year ended December 30, 2023.
- The company issued a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2).
- Management held/scheduled a conference call to discuss results with investors.